Literature DB >> 11259414

Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities.

F Galbiati1, J A Engelman, D Volonte, X L Zhang, C Minetti, M Li, H Hou, B Kneitz, W Edelmann, M P Lisanti.   

Abstract

Caveolin-3, a muscle-specific caveolin-related protein, is the principal structural protein of caveolae membrane domains in striated muscle cells. Recently, we identified a novel autosomal dominant form of limb-girdle muscular dystrophy (LGMD-1C) in humans that is due to mutations within the coding sequence of the human caveolin-3 gene (3p25). These LGMD-1C mutations lead to an approximately 95% reduction in caveolin-3 protein expression, i.e. a caveolin-3 deficiency. Here, we created a caveolin-3 null (CAV3 -/-) mouse model, using standard homologous recombination techniques, to mimic a caveolin-3 deficiency. We show that these mice lack caveolin-3 protein expression and sarcolemmal caveolae membranes. In addition, analysis of skeletal muscle tissue from these caveolin-3 null mice reveals: (i) mild myopathic changes; (ii) an exclusion of the dystrophin-glycoprotein complex from lipid raft domains; and (iii) abnormalities in the organization of the T-tubule system, with dilated and longitudinally oriented T-tubules. These results have clear mechanistic implications for understanding the pathogenesis of LGMD-1C at a molecular level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259414     DOI: 10.1074/jbc.M100828200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  159 in total

Review 1.  Caveolin-deficient mice: insights into caveolar function human disease.

Authors:  B Razani; M P Lisanti
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Cholesterol, lipid rafts, and disease.

Authors:  Kai Simons; Robert Ehehalt
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 3.  The role of endocytosis in activating and regulating signal transduction.

Authors:  Emma R Andersson
Journal:  Cell Mol Life Sci       Date:  2011-11-24       Impact factor: 9.261

Review 4.  Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins.

Authors:  Michael J Ackerman; Peter J Mohler
Journal:  Circ Res       Date:  2010-08-20       Impact factor: 17.367

Review 5.  Organization of junctional sarcoplasmic reticulum proteins in skeletal muscle fibers.

Authors:  Virginia Barone; Davide Randazzo; Valeria Del Re; Vincenzo Sorrentino; Daniela Rossi
Journal:  J Muscle Res Cell Motil       Date:  2015-09-15       Impact factor: 2.698

6.  Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation.

Authors:  William Schubert; Federica Sotgia; Alex W Cohen; Franco Capozza; Gloria Bonuccelli; Claudio Bruno; Carlo Minetti; Eduardo Bonilla; Salvatore Dimauro; Michael P Lisanti
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

7.  Mechanosensitive channel properties and membrane mechanics in mouse dystrophic myotubes.

Authors:  Thomas M Suchyna; Frederick Sachs
Journal:  J Physiol       Date:  2007-01-25       Impact factor: 5.182

Review 8.  Caveolae as organizers of pharmacologically relevant signal transduction molecules.

Authors:  Hemal H Patel; Fiona Murray; Paul A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

9.  Mechanism of caveolin filament assembly.

Authors:  Imma Fernandez; Yunshu Ying; Joseph Albanesi; Richard G W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-07       Impact factor: 11.205

10.  Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.

Authors:  Daniela Volonte; Aaron J Peoples; Ferruccio Galbiati
Journal:  Mol Biol Cell       Date:  2003-08-07       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.